GEN Exclusives

More »

GEN News Highlights

More »
Aug 9, 2007

Ipsen Obtains EU Marketing Approval for Short Stature Drug

  • Tercica and Ipsen received European marketing authorization for Increlex® for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency.

    Tercica will receive a milestone payment of EUR 15 million, or approximately $20.55 million, from its EU marketing partner, Ipsen. Since Increlex is under orphan drug designation, the drug will have a 10-year exclusivity period in the EU. It will be sold as a 10-mg/mL solution.

    Tercica has been marketing Increlex in the U.S. since early 2006. The drug’s active ingredient is recombinant human insulin-like growth factor-1 (IGF-1). IGF-1 is the direct mediator of growth hormone’s effect on statural growth and must be present for normal growth of bones and cartilage in children.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?